Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...

Otsuka Holdings Co ( ($JP:4578) ) just unveiled an update. Otsuka Holdings Co., Ltd. reported a significant increase in their nonconsolidated ...

Wells Fargo notes that Vera Therapeutics (VERA) shares are down about 20% today, which the firm attributes to competitor Otsuka saying they ...

Shares of Vera Therapeutics (NASDAQ:VERA) lost ~20% on Friday to reach a new 52-week low, in a move attributed to a potential market launch of a rival kidney disease therapy from Otsuka Holdings ...

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.

JPMorgan analyst Anupam Rama says Vera Therapeutics (VERA) shares closed down 20% on Friday, driven by Otsuka’s announcement that the biologics ...

Otsuka licensed rights to Lupkynis in various ex-US markets including the EU, Japan and the UK in 2020, with Aurinia retaining rights to the drug in the US and its home market of Canada.

Hirofumi Otsuka is Co-Head of the Specialized Finance Department for the Americas at SMBC. In this capacity, he is responsible for project finance and public finance activities in both North America ...

Greg Keeley, who most recently served as the senior vice president of platforms and technology at TD, will join SMBC in April ...

Takeda Healthcare Philippines, Inc. and Otsuka-Solar Philippines, Inc., with the support of the Embassy of Japan in the Ph ...